Nicox S.A. (EPA:ALCOX)

France flag France · Delayed Price · Currency is EUR
0.3320
+0.0160 (5.06%)
Sep 4, 2025, 1:43 PM CET
5.06%
Market Cap22.82M
Revenue (ttm)7.86M
Net Income (ttm)-22.39M
Shares Out72.22M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,149,261
Average Volume1,815,825
Open0.3575
Previous Close0.3160
Day's Range0.3315 - 0.3875
52-Week Range0.1400 - 0.6500
Beta0.80
RSI36.83
Earnings DateSep 23, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 28
Stock Exchange Euronext Paris
Ticker Symbol ALCOX
Full Company Profile

Financial Performance

In 2024, Nicox's revenue was 7.86 million, an increase of 13.85% compared to the previous year's 6.90 million. Losses were -22.39 million, 7.23% more than in 2023.

Financial Statements

News

There is no news available yet.